Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SANDOZ AND WYETH ARE IN TEMAZEPAM ANDA BATTLE

Executive Summary

SANDOZ AND WYETH ARE IN TEMAZEPAM ANDA BATTLE to market a soft elastic gelatin version of the anti-insomnia drug in the U.S. Wyeth initiated the ANDA race for a new soft elastic gelatin version of the product with an ANDA suitability petition to FDA in January ("The Pink Sheet" Jan. 28, T&G-7). Sandoz answered with an ANDA suitability petition of its own on March 27 for a soft elastic gelatin product which it intends to call Restoril LC (liquid capsule). In apparent preparation for the patent expiration on temazapam in January 1984, Sandoz submitted an NDA for Restoril LC in August 1983. However, the firm was told by FDA that an NDA for the soft elastic gelatin formulation would require "total characterization of the clinical performance. . . ." Sandoz argues in its ANDA suitability petition that the product qualifies for an ANDA under the new mutant rules for products containing the identical active ingredient with a different dosage form and/or strength. The existing Restoril product is marketed at 15 mg and 30 mg strengths in hardshell caps. The ANDAs are for 10 mg and 20 mg. soft elastic gelatin forms. The jockeying between Sandoz and Wyeth for a new ANDAed dosage of temazepam is one of the first head-to-head battles between major brandname firms to use the new generic approval route for a top-selling product. Restoril ranked 50th among retail products in total Rxs in 1984. The temazepam situation arises from the history of the product: Wyeth owns the patent and markets the product outside the U.S.; Sandoz has licensing rights to the original hardshell cap product in the U.S. Wyeth pointed out in its ANDA petitions for 10 mg and 20 mg dosage formulations that it has been marketing the soft elastic gelatin product since 1977 in overseas markets. "The composition of the product we propose to market," Wyeth said, "would be the same as that of the product (Normison) currently marketed by Wyeth Internatl. Ltd. That product is marketed in 39 countries and has been approved in 21 other countries, but not yet marketed. Sandoz attempts to piggyback off the Wyeth internatl. experience. Sandoz contends: "The composition of the product we propose to market . . . is the same as that of the product (Normison) currently marketed by Wyeth Internatl. Ltd. The inactive ingredient and capsule shell constitutents are all safe substances acceptable for use in pharmaceutical products in the U.S." The Sandoz petition also references studies on LC presumably prepared for the previous NDA filing -- two sleep lab studies "to evaluate the LC at 20 mg on the usual polysomnography parameters" and a 24-subject crossover bioavailability study.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel